40 results about "Cardiac functioning" patented technology

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.The invention further relates to complementary parts of such systems that work best in combination.Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters / sheaths / shafts to yield a robust assessment of cardiac performance.Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and / or after deploying a VAD.

A blood pump (1) for patient heart support comprises a flow cannula (4) with a distal end (10) and a proximal end (11) opposite the distal end (10). The distal end (10) of the flow cannula (4) is configured to connect to the patient's heart or a blood vessel, thereby establishing fluid communication between the blood pump (1) and the patient's heart and blood vessel, respectively. The flow cannula (4) comprises a distal portion (5) with said distal end (10) and a proximal portion (6) with said proximal end (11). Furthermore, the flow cannula (4) comprises an intermediate portion (7) attached to the distal portion (5) and the proximal portion (6). The intermediate portion (7) is designed to be twisted with less force than the distal portion (5) and the proximal portion (6). The intermediate portion (7) is configured to be completely occluded by twisting.At least a portion of the intermediate portion (7), either alone or in combination with the distal portion (5), is adapted to be permanently attached to the patient's heart or a blood vessel.

A system and method for cardiovascular monitoring and reporting are disclosed. The system (CV monitoring system) includes a data analysis system and an in-ear biosensor system that preferably includes left and right earbuds. The earbuds include infrasound / vibration sensors that detect biosignals from the individual including signals associated with cardiovascular activity (CV signals). The analysis system calculates cardiovascular function measurements (CV function measurements) based upon the CV signals. The CV monitoring system uses machine learning to predict blood pressure (BP) measurements of the individual based upon the CV signals and the calculated CV function measurements. In an embodiment, the CV monitoring system includes an EKG detection system that detects EKG signals associated with heart function. The analysis system can calculate additional CV function measurements from the EKG signals to augment the CV function measurements calculated from the CV signals, and predict BP measurements using the full complement of CV function measurements.

This invention relates to a method, control device, and robot for robot-assisted rehabilitation training. The method includes: acquiring cardiac function classification data and physiological data of a target subject, the physiological data being sensed in real time by sensors configured on the robot; determining a rehabilitation training method matching the target subject's cardiac function based on the cardiac function classification data and the real-time sensed physiological data; enabling the robot's tactile hand to contact and / or grasp the target subject's hand based on the robot's visual detection data; and adjusting the movement state of the robotic arm and tactile hand based on the determined rehabilitation training method and the real-time sensed physiological data, so as to assist the target subject in rehabilitation training via the tactile hand. Therefore, this invention can provide continuous and accurate physiological monitoring and adaptive adjustment of rehabilitation training intensity for the target subject during rehabilitation training, thereby significantly improving the safety and effectiveness of rehabilitation training.

This invention discloses an in-situ constructed FAP-targeting CAR-T nanoliposome delivery system, its preparation method, and its applications, belonging to the field of biomedical technology. This invention provides a biocompatible nanoliposome delivery system whose surface is modified with a CD3 antibody that can capture T cells through circulation, delivering plasmid DNA encoding FAP-CAR into the T cells, thus in-situ transforming T cells into CAR-T cells in vivo. The nanoliposome delivery system provided by this invention can significantly alleviate myocardial fibrosis caused by myocardial infarction and restore cardiac function, providing a research basis for the clinical application of CAR-T cell therapy based on in-situ nanoengineering in myocardial infarction.

This invention relates to a traditional Chinese medicine composition for treating coronary heart disease and its preparation method, comprising the following raw materials in parts by weight: ginseng 3-18 parts, astragalus 6-30 parts, centella asiatica 6-30 parts, abscissus 6-30 parts, salvia miltiorrhiza 6-30 parts, chuanxiong rhizome 5-30 parts, safflower 5-20 parts, anemarrhena rhizome 6-30 parts, salvia miltiorrhiza seed 3-12 parts, prepared licorice root 3-12 parts, and stir-fried yam 5-30 parts. This composition can significantly improve cardiac function in rats with coronary heart disease, especially enhancing myocardial contractility; simultaneously, it can regulate lipid metabolism in model mice and reduce the formation of atherosclerotic plaques. Furthermore, in both of the aforementioned models, this composition can significantly reduce the expression levels of inflammatory factors such as interleukin-1β, interleukin-6, and tumor necrosis factor-α, thereby exerting an anti-inflammatory effect. In conclusion, this composition has promising application prospects in the prevention and treatment of coronary heart disease.

Systems, devices and methods are provided for supporting cardiac function. One system comprises an implantable intracardiac device comprising a motor and a pump, a transmitting resonator comprising a magnetic coil and configured to transmit a first level of power through an outer skin surface of the patient and a receiving resonator configured for implantation within the patient, comprising a magnetic coil and configured to transmit a second level of power to the motor within the implanted device. A controller is coupled to the transmitting resonator and configured to control the resonators and other parameters in the system such that the second level of power remains at or above a threshold level, thereby ensuring that the pump will continuously pump blood through the heart at a sufficient rate regardless of any changes in the system, such as power loss due to transmission inefficiencies and / or changes in the relative positions between the transmitting and receiving coils.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.

Provided in the present application are a biomagnetic signal-based four-dimensional cardiac function imaging method and device. The method comprises: acquiring a cardiac magnetic signal of a subject to be tested and dynamic structure information of a target torso part within a full cardiac cycle, wherein the target torso part at least comprises two lungs, a torso, and a heart chamber and a pericardium structure thereof, and the dynamic structure information comprises a contour structure and a plurality of frames of dynamic images; performing spatial registration on the dynamic structure information and a sensor acquiring the cardiac magnetic signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; calculating and reconstructing a cardiac electrical excitation activity based on the dynamic structure information, the coordinates of the sensor, and the cardiac magnetic signal to obtain a calculation and reconstruction result; and converting the calculation and reconstruction result into a four-dimensional visualization image.

The application belongs to the technical field of biological nanomaterials, and particularly relates to a nano-enzyme material and a preparation method and application thereof. The application reacts dimethyl imidazole and metal salt in an aqueous solution to obtain a metal-dimethyl imidazole composite material solution, wherein the metal salt comprises copper salt and / or zinc salt; and reacts the metal-dimethyl imidazole composite material solution and tannic acid to obtain a nano-enzyme material. The nano-enzyme material provided by the application has excellent antioxidant enzyme-like catalytic activity and good biocompatibility, can effectively remove abnormally increased reactive oxygen species (ROS) in the process of myocardial infarction and myocardial ischemia-reperfusion injury, inhibit inflammatory response and myocardial cell apoptosis, improve the mitochondrial function state, thereby promoting the repair of damaged myocardial tissue and significantly improving the cardiac function, and provides a new technical solution for the treatment of myocardial infarction and related ischemic cardiovascular diseases.

This invention discloses the use of AXL inhibitors in the preparation of drugs for treating heart failure, relating to the pharmaceutical field. This invention provides the application of AXL inhibitors in drugs for treating heart failure, wherein the inhibitors can significantly inhibit abnormal fibroblast activation and significantly improve cardiac function in mice with heart failure.

This invention relates to HeartTAC, an antibody protein that targets and degrades calprotectin, and its applications, belonging to the field of biomedical technology. This invention provides HeartTAC, an antibody protein that targets and degrades calprotectin, the amino acid sequence of which is shown in SEQ ID NO. 6 or SEQ ID NO. 4. This invention employs an extracellular targeted protein degradation scheme to construct HeartTAC, an antibody protein that targets and degrades calprotectin. This protein exhibits good targeting specificity to the heart, can degrade calprotectin in the heart, can significantly improve cardiac function, alleviate cardiac fibrosis, and has good safety profile. It opens up an important new direction for the prevention and control of cardiovascular diseases and has promising application prospects.

The invention discloses a text prompt type heart function intelligent evaluation method based on a visual language large model. The method comprises the following steps that 1, an echocardiography mark data set is constructed; 2, dividing four chambers of the heart; step 3, hierarchical feature learning; 4, performing multi-scale feature fusion; and 5, predicting the cardiac function (ejection fraction). According to the method, the heart can be modeled into a multi-scale semantic system, and features from macroscopic chamber dynamics to microstructure motion are captured through a hierarchical feature learning mechanism. Deep integration of imaging data and clinical knowledge is realized by aligning hierarchical visual features with professional medical descriptions in a shared semantic space. The method has excellent performance in the aspect of ejection fraction prediction.

The application discloses application of SFRP3 in prevention and treatment of dilated cardiomyopathy, and belongs to the technical field of biological medicine. The application down-regulates SFRP3 expression in myocardial cells by means of gene interference, RNA interference technology, antibody or small molecule inhibitor, etc. to treat dilated cardiomyopathy, realizes the purposes of improving heart function, reducing cardiac dilatation, improving myocardial fibrosis and effectively promoting myocardial repair, and provides a more effective and low-side-effect treatment method for treatment of dilated cardiomyopathy. The treatment idea provided by the application can not only relieve symptoms of dilated cardiomyopathy, but also regulate physiological processes of heart cells at a molecular level, and provides a new idea for clinical treatment of dilated cardiomyopathy.

Methods and systems are disclosed for creating and using a neural network model to estimate a cardiac parameter of a patient, and using the estimated parameter in providing blood pump support to improve patient cardiac performance and heart health. Particular adaptations include adjusting blood pump parameters and determining whether and how to increase or decrease support, or wean the patient from the blood pump altogether. The model is created based on neural network processing of data from a first patient set and includes measured hemodynamic and pump parameters compared to a cardiac parameter measured in situ, for example the left ventricular volume measured by millar (in animals) or inca (in human) catheter. After development of a model based on the first set of patients, the model is applied to a patient in a second set to estimate the cardiac parameter without use of an additional catheter or direct measurement.

The disclosure provides compositions comprising an inhibitory nucleic acid targeting IncExACTI, and methods of use thereof to improve cardiac function in a subject in need thereof. Specifically, the disclosure provides a cardiac long noncoding RNA (IncRNA), referred as IncExACT 1 (SEQ ID NO: 1), and inhibitory nucleic acids targeting IncExACT 1 for reducing expression of IncExACT 1 and / or Dachsous cadherin-related 2 (DCHS2) in a cell, e.g., a cell in a subject for improving cardiac function in a subject, wherein the subject has pathological cardiac hypertrophy and / or heart failure.

Systems, devices and methods are provided for supporting cardiac function. One system comprises an implantable intracardiac device comprising a motor and a pump, an external energy source and a transmitting resonator comprising a magnetic coil and configured to receive a first level of power from the external energy source and transmit a second level of power through an outer skin surface of the patient. The system further comprises a receiving resonator configured for implantation within the patient, comprising a magnetic coil and configured to transmit a third level of power to the motor within the implanted device. The third level of power is at least 40% of the first level of power, thereby ensuring that the pump will continuously pump blood through the heart at a sufficient rate regardless of any changes in the system, such as power loss due to transmission inefficiencies and / or changes in the relative positions between the transmitting and receiving coils.

The present application relates to the technical field of genetic engineering, in particular to a kind of gene medicine for treating PNPLA2 mutation arrhythmogenic cardiomyopathy and its preparation method and application.The effective component of gene medicine provided in the present application includes shuttle plasmid;The shuttle plasmid includes AAV9 carrier and PNPLA2 gene.The present application delivers normal PNPLA2 gene by AAV9 carrier, repairs the lipid metabolism disorder caused by mutation, reduces the fat deposition in myocardium, and then improves the pathological changes of ACM.By restoring the function of PNPLA2 gene, the process of myocardial fibrosis can be effectively inhibited, and the heart function can be improved.The present application uses myocardial specific promoter cTnT to ensure that PNPLA2 gene is only expressed in myocardium, so as to improve the targeting of gene therapy, and avoid the side effects caused by systemic expression.This strategy can effectively reduce the side effects of gene therapy, and ensure the accuracy and safety of treatment.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

This application provides a multi-source cardiac state assessment system based on adaptive weight allocation. The system includes: a signal quality assessment module for real-time calculation of the signal quality index of electrocardiogram (ECG), photoplethysmography (PPG), and echocardiography signals; a user motion state recognition module for identifying the user's current motion state; an adaptive weight allocation engine for dynamically allocating fusion weights for the ECG, PPG, and echocardiography signals in the cardiac state assessment based on the signal quality index and the user's motion state; and a cardiac state trend score generator for calculating a comprehensive trend score based on the weighted fusion features. The comprehensive trend score reflects the overall state and trend of cardiac function. This technical solution achieves continuous, personalized, and highly robust monitoring and risk warning of cardiac function.

This invention provides a cardiac-targeting degradative protein αNPR1-HE4 and its applications, belonging to the field of protein drug technology. The amino acid sequence of the degradative protein αNPR1-HE4 is any one of the amino acid sequences shown in SEQ ID NO.2~SEQ ID NO.4. The cardiac-targeting degradative protein αNPR1-HE4 provided by this invention can significantly improve cardiac function and cardiac fibrosis in mice with myocardial infarction, exhibiting good safety and excellent cardiac targeting, and has promising clinical application prospects.

The invention relates to a headphone (1), in particular an on-ear, over-ear and / or in-ear headphone, with at least one transducer (2) for generating and detecting at least ultrasonic waves (3), and with a control unit (4) which can determine a bodily function, in particular a cardiac function and / or a respiratory function, of a wearer (5) of the headphone (1) based on the generated and detected ultrasonic waves (3). Furthermore, the at least one transducer (2) is a MEMS transducer (2), in particular a broadband MEMS transducer.Furthermore, the invention relates to a method for determining a bodily function, in particular a cardiac function and / or respiratory function, of a wearer (5) of headphones (1), in particular of on-ear headphones, over-ear headphones and / or in-ear headphones, in which ultrasound waves (3) are generated by means of a MEMS transducer (2), in particular of a broadband MEMS transducer, of the headphones (1), in which the ultrasound waves (3) are detected by means of the MEMS transducer (2), in particular of the broadband MEMS transducer, and / or a further microphone, and in which the bodily function of the wearer (5) of the headphones (1) is determined by means of a control unit (4) of the headphones (1) on the basis of the generated and detected ultrasound waves (3), as well as a MEMS transducer (2), in particular a broadband MEMS transducer, for headphones (1) and / or a method for determining a bodily function.

The application discloses a new application of a substance increasing the content or activity of PARKIN in treating and / or preventing cardiovascular diseases. The application proves by transgenic and gene therapy means that increasing the content of PARKIN can significantly inhibit the activation of a cGAS-STING signal pathway and the downstream inflammatory response, thereby significantly improving the heart function, reducing the myocardial inflammatory response and myocardial fibrosis. The application provides a new drug target and treatment strategy for the prevention and treatment of cardiovascular diseases, and has important clinical application value.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.